TITLE

Sublingual fentanyl citrate for cancer-related breakthrough pain: a pilot study

AUTHOR(S)
Zeppetella, G.
PUB. DATE
July 2001
SOURCE
Palliative Medicine;Jul2001, Vol. 15 Issue 4, p323
SOURCE TYPE
Academic Journal
DOC. TYPE
Article
ABSTRACT
The effects of sublingual fentanyl citrate (SLFC) were assessed in 11 hospice inpatients with cancer-related breakthrough pain. Patients were asked to rate their pain, using a visual analogue scale, before SLFC, then after 3, 5, 10, 15, 30, 45 and 60 min. Six patients (55%) had reductions in pain scores at 10 min and nine patients (82%) at 15 min. Ratings for SLFC were very good (18%), good (36%), moderate (28%), and bad (18%). Compared to the usual breakthrough medication, SLFC was better (46%), the same (36%), or worse (18%). Advantages of SLFC included ease of use, quick onset of action and no associated drowsiness. No systemic adverse events were noted, but two patients reported dry mouth and two a bitter taste. Two patients found it difficult to retain the medication under the tongue. Seven patients (64%) said they would continue to use SLFC. Sublingual fentanyl citrate appears safe and well tolerated by these patients. Randomized placebo-controlled and dose ranging studies are required to confirm these findings.
ACCESSION #
4762824

 

Related Articles

  • Transdermal fentanyl for the management of cancer pain: a survey of 1005 patients. Radbruch, L.; Sabatowski, R.; Petzke, F.; Brunsch-Radbruch, A.; Grond, S.; Lehmann, K.A. // Palliative Medicine;Jul2001, Vol. 15 Issue 4, p309 

    Transdermal fentanyl was released in Germany in 1995. From October 1996 to February 1998 transdermal treatment was documented for 1005 patients (506 men and 499 women with a mean age of 60 years, range 20-92 years) with chronic pain in an open survey including 290 physicians from hospitals and...

  • A successful study comparing the recently developed oral transmucosal fentanyl citrate (OTFC) with immediate release opioids for cancer breakthrough pain. Nugent, M; Hanks, G; Bush, M // Palliative Medicine;May2000, Vol. 14 Issue 3, p229 

    Evaluates the use of oral transmucosal fentanyl citrate (OTFC) for cancer breakthrough pain in Great Britain. Comparison with immediate release opioids; Definition of breakthrough pain; Safety and effectiveness of OTFC.

  • Spray improved pain management in cancer patients.  // Hem/Onc Today;5/25/2013, Vol. 14 Issue 10, p56 

    The article discusses the findings of a randomized study which revealed the therapeutic use of fentanyl sublingual spray in improving a number of pain and adverse event categories in a cohort of patients with several types of cancer.

  • An effective way to manage breakthrough pain. Scholz, Mary // RN;May99, Vol. 62 Issue 5, p102 

    Replies to an inquiry about the management of pain in a patient with metastatic prostate cancer. Use of fentanyl to help control acute flare-ups of cancer pain; Precautions in administering the drug.

  • Onsolis to treat cancer pain.  // Monthly Prescribing Reference;Nov2009, Vol. 25 Issue 11, pA21 

    The article reports that the fentanyl buccal soluble film, Onsolin from Meda AB, is available for the management of pain in cancer patients aged 18 or above and who are tolerant to opiod therapy.

  • Fentanyl.  // Reactions Weekly;Jul2014, Vol. 1509 Issue 1, p17 

    The article presents a case study of a patient who experienced vomiting which resulted in death after being treated with fentanyl pectin nasal spray for cancer pain.

  • Nebulized and intranasal fentanyl in the management of cancer-related breakthrough pain. Zeppetella, G. // Palliative Medicine;Jan2000, Vol. 14 Issue 1, p57 

    Studies the use of nebulized and intranasal fentanyl in the management of cancer-related breakthrough pain. Case histories of cancer patients with breakthrough pain; Overview of breakthrough pain; Ideal delivery systems for breakthrough analgesia; Comparison of fentanyl effectiveness and...

  • Fentanyl.  // Reactions Weekly;3/9/2013, Issue 1443, p16 

    An abstract of the article "Complete atrioventricular block associated with transdermal fentanyl treatment for cancer pain," by D. Tok and colleagues is presented.

  • Intranasal fentanyl of value for cancer pain.  // PharmacoEconomics & Outcomes News;4/2/2011, Issue 625, p7 

    The article discusses research on the cost effectiveness of intranasal fentanyl spray for cancer pain treatment, by D. C. Vissers and colleagues, published in "Value in Health."

Share

Read the Article

Courtesy of THE LIBRARY OF VIRGINIA

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics